Tubize Fin (Belgium) Analysis
| TUB Stock | EUR 146.00 1.80 1.25% |
Tubize Fin is fairly valued with Real Value of 145.45 and Hype Value of 146.0. The main objective of Tubize Fin stock analysis is to determine its intrinsic value, which is an estimate of what Tubize Fin is worth, separate from its market price. There are two main types of Tubize Fin's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Tubize Fin's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Tubize Fin's stock to identify patterns and trends that may indicate its future price movements.
The Tubize Fin stock is traded in Belgium on Euronext Brussels, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Belgium. Tubize Fin is usually not traded on All Saints ' Day, Christmas Day, New Year 's Day, Easter Sunday, Easter Monday, International Workers ' Day, Belgian National Day, Assumption of Mary. Tubize Stock trading window is adjusted to Europe/Brussels timezone.
Tubize |
Tubize Stock Analysis Notes
About 57.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tubize Fin recorded earning per share (EPS) of 7.19. The entity last dividend was issued on the 3rd of May 2022. The firm had 2:1 split on the 17th of June 2005. Financire de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. The companys products in pipeline include UCB0942 for drug resistant epilepsy UCB3491 for infantile epilepsy UCB0599 for Parkinsons disease UCB7858UCB0159 for auto-inflammatory diseases UCB6673 to treat immunological diseases UCB4144VR942 to treat asthma seletalisib for treating Sjrgens syndrome dapirolizumab pegol for systemic lupus erythematosus bimekizumab to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis rozanolixizumab to treat immune thrombocytopenia and myasthenia gravis and romosozumab for post-menopausal osteoporosis and osteoporosis in men. TUBIZE FIN operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. To find out more about Tubize Fin contact the company at 32 497 51 52 08 or learn more at https://www.financiere-tubize.be.Tubize Fin Investment Alerts
| The company has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Tubize Fin until it has trouble settling it off, either with new capital or with free cash flow. So, Tubize Fin's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tubize Fin sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tubize to invest in growth at high rates of return. When we think about Tubize Fin's use of debt, we should always consider it together with cash and equity. | |
| Tubize Fin has accumulated about 1.02 M in cash with (1.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 57.0% of the company outstanding shares are owned by corporate insiders |
Tubize Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tubize Fin's market, we take the total number of its shares issued and multiply it by Tubize Fin's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 26th of February, Tubize Fin has the Risk Adjusted Performance of 0.0821, semi deviation of 1.57, and Coefficient Of Variation of 958.49. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tubize Fin, as well as the relationship between them. Please validate Tubize Fin coefficient of variation, variance, and the relationship between the downside deviation and standard deviation to decide if Tubize Fin is priced more or less accurately, providing market reflects its prevalent price of 146.0 per share.Tubize Fin Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tubize Fin middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tubize Fin. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Tubize Fin Outstanding Bonds
Tubize Fin issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tubize Fin uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tubize bonds can be classified according to their maturity, which is the date when Tubize Fin has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Tubize Fin Predictive Daily Indicators
Tubize Fin intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tubize Fin stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tubize Fin Forecast Models
Tubize Fin's time-series forecasting models are one of many Tubize Fin's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tubize Fin's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Tubize Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tubize Fin prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tubize shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tubize Fin. By using and applying Tubize Stock analysis, traders can create a robust methodology for identifying Tubize entry and exit points for their positions.
Financire de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. The companys products in pipeline include UCB0942 for drug resistant epilepsy UCB3491 for infantile epilepsy UCB0599 for Parkinsons disease UCB7858UCB0159 for auto-inflammatory diseases UCB6673 to treat immunological diseases UCB4144VR942 to treat asthma seletalisib for treating Sjrgens syndrome dapirolizumab pegol for systemic lupus erythematosus bimekizumab to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis rozanolixizumab to treat immune thrombocytopenia and myasthenia gravis and romosozumab for post-menopausal osteoporosis and osteoporosis in men. TUBIZE FIN operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tubize Fin to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Additional Tools for Tubize Stock Analysis
When running Tubize Fin's price analysis, check to measure Tubize Fin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tubize Fin is operating at the current time. Most of Tubize Fin's value examination focuses on studying past and present price action to predict the probability of Tubize Fin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tubize Fin's price. Additionally, you may evaluate how the addition of Tubize Fin to your portfolios can decrease your overall portfolio volatility.